William R. Brugge, MD, is the past director of Gastrointestinal Endoscopy at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. He is interested in the diagnosis and treatment of early gastrointestinal malignancies.
William R. Brugge, MD is the director of the Pancreas-Biliary Center at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. You may contact him via email: WBrugge@partners.org.
Dr. Brugge is an active clinical consultant in gastroenterology and gastrointestinal endoscopy, focusing on patients with complex pancreatic diseases. His research has focused on the early diagnosis of pancreatic cancer, developing a variety of endoscopic techniques to aspirate malignant and pre-malignant lesions of the pancreas, including mucinous cysts, intra-ductal tumors, and masses. He also performs therapeutic endoscopic procedures such as ERCP, stent placement, FNA and EMR. Currently he is currently conducting a trial of injection therapy for pancreatic cystic neoplasms.
Dr. Brugge is a Fellow of the American Society of Gastrointestinal Endoscopy, the American College of Gastroenterology and the American Gastroenterological Association. Dr. Brugge has published more than 200 manuscripts in the field of gastrointestinal endoscopy.
My clinical research program focuses on the early detection of gastrointestinal malignancy using advanced endoscopic techniques. Endoscopic confocal endomicroscopy is a new endoscopic technique for detecting neoplasms in the GI tract. We also use advanced endoscopic techniques for the detection of early pancreatic malignancy arising from cystic lesions of the pancreas. Confocal needle imaging is performed using a novel catheter placed within a EUS needle and guided into a cystic lesion. A variety of cyst fluid markers are used to enhance the diagnostic accuracy of EUS imaging alone. We have examined the accuracy of CEA and cytology in the diagnosis of mucinous cystic lesions. Currently we are investigating new molecular markers such as kRAS and GNAS. For a list of current research projects, please visit Dr. Brugge's research page.
We are currently directing several clinical trials, including EUS guided Abraxane injection of pancreas cysts and a pilot study of confocal endomicroscopy of pancreatic cysts (visit the Clinical Trials website of the National Institutes of Health for more information).
1. Cystic pancreatic neuroendocrine tumors: the value of cytology in preoperative diagnosis.
Morales-Oyarvide V, Yoon WJ, Ingkakul T, Forcione DG, Casey BW, Brugge WR, Fern?ndez-del Castillo C, Pitman MB. Cancer Cytopathol. 2014 Jun;122(6):435-442.
2. Oh HC, Brugge WR.EUS-guided pancreatic cyst ablation: a critical review. Gastrointest Endosc. 2013 Jan 12.
3. Recurrences are common after endoscopic ampullectomy for adenoma in the familial adenomatous polyposis (FAP) syndrome.Ma T, Kelsey PB, Forcione DG, Brugge WR, Syngal S, Chung DC. Surg Endosc. 2014 Aug;28(8):2349-56.44
4.Brugge WR. Curr Opin Gastroenterol. 2013 Sep;29(5):559-65.
Endoscopic approach to the diagnosis and treatment of pancreatic disease.
5.Das KK, Forcione DG, Bounds BC, Brugge WR, Das KM.Gut. 2013 Nov 25. mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN).
6. Characterization of epithelial subtypes of intraductal papillary mucinous neoplasm of the pancreas with endoscopic ultrasound and cyst fluid analysis. Yoon WJ, Daglilar ES, Pitman MB, Brugge WR. Endoscopy. 2014 Dec;46(12):1071-7.7.
7. Controlled swine bile duct ablation with a bipolar radiofrequency catheter Daglilar ES, Yoon WJ, Brugge WR 2013 May;77(5):815-9
8. Peritoneal seeding in intraductal papillary mucinous neoplasm of the pancreas patients who underwent endoscopic ultrasound-guided fine-needle aspiration: the PIPE Study. Yoon WJ, Daglilar ES, Fern?ndez-del Castillo C, Mino-Kenudson M, Pitman MB, Brugge WR. Endoscopy. 2014 May;46(5):382-7.
Endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA) is performed with a linear echoendoscope using endoscopic imaging as well as ultrasound guidance. During FNA, the needle can be seen entering the pancreas. For cystic lesions, fluid is removed. For solid lesions, cytologic material is sampled.
Cystic pancreatic lesions are being detected with increasing frequency, and pancreatic cystic neoplasms account for the majority of these lesions. Designed for medical professionals, this video illustrates the use of endoscopic ultrasound and cyst fluid analysis in differential diagnosis of cystic pancreatic lesions.
Up until the mid-1990s, physicians knew little about the relationship between pancreatic cysts and pancreatic cancer. But collaborative research conducted by gastroenterologists, surgeons, radiologists, and pathologists at the Massachusetts General Hospital Digestive Healthcare Center has led to a much greater understanding of pancreatic cystadenomas and what makes some cysts progress to cancer. These advances are opening up new therapies to target this deadly cancer early on, when it is most treatable.
Patients seeking care for pancreatic and biliary system disorders at Massachusetts General Hospital’s Digestive Healthcare Center receive the latest in diagnostic and therapeutic treatments from a collaborative team of experts, including gastroenterologists, interventional endoscopists, pathologists, medical oncologists, surgeons, radiation oncologists, and radiation therapists.
Phone 2: 617-724-3715
Phone 2: 617-724-3715
Call the Massachusetts General Hospital physician referral service at 800-711-4644.
Mass General accepts most health insurance plans. Find out what you need to know before coming to Mass General.
Driving to Mass General? Get driving directions or locate a parking lot on the hospital's main campus.